Featured Image
Perspectives
The availability of novel anticoagulants, particularly apixaban, have been a major advance in the prevention of stroke in atrial fibrillation. There is a pressing need for a high-quality randomized trial of apixaban 2.5 mg po bid versus warfarin adjusted dose versus matching double dummy placebo to fully assess the risks and benefits in this population.
Dr Peter A McCullough
Baylor University Medical Center at Dallas
Read the Original
This page is a summary of: Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro, Clinical Journal of the American Society of Nephrology, October 2016, American Society of Nephrology,
DOI: 10.2215/cjn.02680316.
You can read the full text:
Contributors
The following have contributed to this page
